Objective

The Neuroform Atlas (Stryker Neurovascular, Fremont, CA, USA) is a low-profile laser cut self-expanding nitinol stent designed to provide coil support and wall apposition during aneurysm embolisation. In this study, we performed a meta-analysis of outcomes after treatment with the Neuroform Atlas stent for the purpose of coil embolisation.

Methods

The primary objectives of this meta-analysis were to define the safety (treatment-related complications, neurologic outcomes, mortality rate) and the efficacy (aneurysm occlusion rate) of the treatment of intracranial aneurysms with the Neuroform Atlas stent. A systematic review and meta-analysis was performed by searching PubMed, EMBASE, and the Cochrane CENTRAL Library for all published studies on the treatment of intracranial aneurysms with the Neuroform Atlas device up to 6 April 2020. The review was prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

A total of 14 studies were analysed (577 patients with 593 intracranial aneurysms). The mean age was 58.2 years and 35.6% were male. Technical success of the procedure was 100%. RROC1/RROC2 (Raymond-Roy occlusion classification (RROC) 1/2) (total occlusion/neck remnant) at a mean follow-up of 8.9 months was achieved in 94.8%. RROC3 was 4.9%. All-cause mortality was 1.8% and permanent residual neurological deficit or disability was 2.7%. Overall complications at follow-up were 6.2%.

Conclusion

Our analysis demonstrated good rates of occlusion at follow-up for aneurysms treated with the Atlas device at follow-up. The safety profile appears similar to other low-profile intracranial stents.

中文翻译：

---

Neuroform Atlas 支架治疗颅内动脉瘤的安全性和有效性

客观的

Neuroform Atlas（Stryker Neurovascular，Fremont，CA，USA）是一种低调的激光切割自膨胀镍钛诺支架，旨在在动脉瘤栓塞期间提供线圈支撑和壁对置。在本研究中，我们对使用 Neuroform Atlas 支架进行弹簧圈栓塞治疗后的结果进行了荟萃分析。

方法

这项荟萃分析的主要目的是确定使用 Neuroform Atlas 支架治疗颅内动脉瘤的安全性（治疗相关并发症、神经系统结果、死亡率）和有效性（动脉瘤闭塞率）。通过在 PubMed、EMBASE 和 Cochrane CENTRAL 图书馆中搜索截至 2020 年 4 月 6 日关于使用 Neuroform Atlas 装置治疗颅内动脉瘤的所有已发表研究，进行了系统评价和荟萃分析。该评价是根据首选系统评价和元分析报告项目 (PRISMA) 指南。

结果

共分析了 14 项研究（577 名患者有 593 个颅内动脉瘤）。平均年龄为 58.2 岁，35.6% 为男性。该程序的技术成功率为 100%。RROC1/RROC2（Raymond-Roy 咬合分类（RROC）1/2）（完全咬合/颈部残余）在平均 8.9 个月的随访中达到 94.8%。RROC3 为 4.9%。全因死亡率为 1.8%，永久性残余神经功能缺损或残疾率为 2.7%。随访时的总体并发症为 6.2%。

结论

我们的分析表明，随访时使用 Atlas 装置治疗的动脉瘤的闭塞率很高。安全性似乎与其他薄型颅内支架相似。